-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Proton pump inhibitors are commonly used clinical acid inhibitors, Minainet data shows that in 2022H1 China's public medical institutions terminal proton pump inhibitor sales exceeded 9 billion yuan, product TOP10 only exclusive variety of iprazole enteric-coated tablets achieved positive growth, brand TOP10 rabeprazole sodium enteric-coated capsules topped the list for the first time, vonorazen soared 567.
10%.
Pirazole proton pump inhibitors are deeply trapped in the whirlpool of centralized procurement, and the arrival of new antacids has added new variables to the proton pump inhibitor market
.
Proton pump inhibitor TOP10! Exclusive Lizhu varieties shine, Takeda soars 567%
Proton pump inhibitors are commonly used acid inhibitors in clinical practice and are widely used in the treatment
of acute and chronic digestive diseases.
According to data from Minai.
com, the peak terminal sales of proton pump inhibitors in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) was 36 billion yuan in 2019, and then it showed a downward trend
due to measures such as key monitoring and volume procurement.
In 2021, the sales scale of terminal proton pump inhibitors in China's public medical institutions will be nearly 26.
6 billion yuan, a year-on-year decrease of 13.
95%; In the first half of 2022, its sales scale exceeded 9 billion yuan, down 36.
70%
from the same period last year.
Sales of terminal proton pump inhibitors in public medical institutions in China (10,000 yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
Among the top 10 proton pump inhibitor products, injection and oral regular-release dosage forms accounted for half, and omeprazole sodium for injection, rabeprazole sodium enteric-coated capsules, and rabeprazole sodium enteric-coated tablets ranked in the top three, of which omeprazole sodium for injection and rabeprazole sodium enteric-coated capsules had sales of more than 1 billion yuan
in the first half of the year.
It is worth mentioning that among the 10 products, only Lizhu Pharmaceutical's exclusive variety of ilaprazole enteric-coated tablets achieved positive growth, and the increase was as high as 20.
23%.
。
2022H1 Top 10 terminal proton pump inhibitor products in China's public medical institutions
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
Among the top 10 proton pump inhibitor brands, domestic brands occupy 6 seats, and Jichuan Pharmaceutical's rabeprazole sodium enteric-coated capsules ranked first for the first time, with a market share of more than 10%; Lizhu Group's ilaprazole enteric-coated tablets and injectable iprazole sodium ranked second and third
respectively.
Among the 4 foreign brands on the list, AstraZeneca occupies 2 seats, Takeda Pharmaceutical's sales of vonorazen fumarate tablets soared 567.
10%, and AstraZeneca's omeprazole sodium for injection soared 38%, showing outstanding performance
.
Vonora fumarate tablets were approved for marketing in China in December 2019 and entered the national medical insurance catalogue through negotiations in December 2020, ushering in rapid growth in the market
.
2022H1 Top 10 terminal proton pump inhibitor brand in China's public medical institutions
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
7 PPIs have been collected, tens of billions of miracle drugs have fallen, and the markets of Luoxin, Shiyao and Kang'en Bay have risen sharply
In the six batches of chemical drug collection carried out by the country, a total of 7 varieties of proton pump inhibitors were included
.
Among them, omeprazole oral regular-release dosage form is the third batch of centralized collection varieties, esomeprazole oral regular-release dosage form, pantoprazole oral regular-release dosage form, pantoprazole injection is the fourth batch of centralized collection varieties, esomeprazole injection and lansoprazole injection are the fifth batch of centralized collection varieties, and omeprazole injection is the seventh batch of centralized collection varieties
.
National centralized procurement of proton pump inhibitors
From oral regular-release dosage forms to injections, the two-dose forms of three varieties of proton pump inhibitors, omeprazole, esomeprazole and pantoprazole, have been included in the centralized procurement
.
Omeprazole oral regular-release dosage form is the first proton pump inhibitor to be included in the centralized procurement, and omeprazole injection has also been included in the seventh batch of centralized procurement
.
According to data from Minai.
com, the terminal sales scale of omeprazole in China's public medical institutions exceeded 9.
5 billion yuan in 2016 and 2017.
The market for oreprazole oral regular-release dosage forms continued to expand before collection, falling by 8.
60% for the first time in 2020, 41.
75% in 2021 and 33.
42% in the first half of 2022
.
As one of the winning enterprises, Luoxin Pharmaceutical's omeprazole enteric-coated capsule market share increased from 4.
94% in 2020 to 22.
58% in the first half of 2022, ranking second
in the market.
Sales of terminal omeprazole oral regular-release dosage form in public medical institutions in China (: 10,000 yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
Pantoprazole injection is the first PPI injection to be collected, and it was included in the fourth batch of centralized procurement
at the same time as the oral regular-release dosage form of pantoprazole.
According to data from Minai.
com, the terminal sales scale of pantoprazole in China's public medical institutions in 2016 and 2017 exceeded 10 billion yuan, of which the sales of pantoprazole injection showed a continuous downward trend since 2017, and the oral regular-release dosage form of pantoprazole began to decline
in 2020.
In 2021, the sales scale of pantoprazole exceeded 3.
3 billion yuan, down 47.
76% year-on-year, and in the first half of 2022, it fell 72.
05%
compared with the same period last year.
Sales of terminal pantoprazole in public medical institutions in China (: million yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
There are 3 winning bidders for the fourth batch of collective varieties of pantoprazole sodium enteric-coated tablets, including Aurobindo, Jiudian Pharmaceutical, and Kangbei
.
The market share of Jiudian Pharmaceutical increased rapidly after the selection of the three enterprises, with the market share of Jiudian Pharmaceutical rising from 15.
47% in 2020 to 27.
94% in the first half of 2022, and the market share of Aurobindo and Combe in 2020 was almost blank, with market shares of 24.
95% and 15.
55%
in the first half of 2022, respectively.
In 2019 and 2020, the terminal sales scale of esomeprazole in China's public medical institutions exceeded 5.
3 billion yuan, and its oral regular-release dosage forms and injections were included in the fourth and fifth batches of centralized procurement
.
Before the centralized procurement, the market of esomeprazole has been firm, with sales falling slightly by 0.
05% in 2020, 11.
05% in 2021 and 63.
21% in the first half of 2022, and the market share of the original manufacturer AstraZeneca fell from 100% in 2013 to 44.
70%
in the first half of 2022 。
Sales of terminal esomeprazole in public medical institutions in China (: million yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
The market share of the winning enterprises of esomeprazole oral regular-release dosage form has increased rapidly from zero, and the market share of Shanxiang Pharmaceutical in the first half of 2022 was 25.
59%, and the market share of Shiyi Ouyi and Chia Tai Tianqing was 13.
86% and 10.
52%,
respectively.
14 varieties have been evaluated, and Luoxin and Shenghe new drugs are rushing to the market
Up to now, 14 varieties of proton pump inhibitors have passed or are deemed to have passed the consistency evaluation
.
Among them, Nanjing Haina Pharmaceutical's omeprazole sodium bicarbonate dry suspension and Hunan Jianlang Pharmaceutical's pantoprazole sodium enteric-coated capsules were exclusive reviews
.
Proton pump inhibitor overrated varieties
Source: Minai.
com China Declaration Progress (MED) database
The number of enterprises evaluated for injection varieties led the oral drugs, with more than 30 companies evaluating omeprazole sodium for injection and pantoprazole sodium for injection, 25 companies evaluating esomeprazole sodium for injection, and 18 companies evaluating lansoprazole for injection
.
Among the 14 evaluated varieties, all proton pump inhibitors that meet the national centralized procurement conditions have been collected
.
Pirazole proton pump inhibitors are deeply trapped in the whirlpool of centralized production, and the market size continues to shrink.
The arrival of new proton pump inhibitors has also added new variables to the proton pump inhibitor market
.
Following the approval of Takeda's vonoraxen fumarate tablets in 2019, the proton pump inhibitor market will welcome two more blockbuster new drugs
in 2022.
On April 8, 2022, Luoxin Pharmaceutical's tigolaxen tablets were approved for marketing, becoming the first self-developed potassium competitive acid blocker (P-CAB) in China; On November 30, 2022, Shenghe Pharmaceutical's class 2.
2 improved new drug dexlansoprazole for injection was approved for marketing, the first in China
.
Source: Minainet database
Note: Minai.
com's "Drug Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission in the data statistics, welcome to correct!
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
